Table 2 Identified proteins uniquely decreased in MPP + -treated cells compared with control
From: Proteomic analysis of S-nitrosylation induced by 1-methyl-4-phenylpyridinium (MPP+)
SPOT # | Accession | Ratio (MPP+/Control) | NAME | Mass (kDa) | pI | ProtScore (a) | % Cov (b) |
|---|---|---|---|---|---|---|---|
15 | GANAB_HUMAN | 0.57 | Neutral alpha-glucosidase AB precursor | 106.9 | 5.74 | 4.25 | 6.1 |
16 | PRD13_HUMAN | 0.65 | PR domain zinc finger protein 13 | 74 | 9 | 2.01 | 4.2 |
17 | ROA2_HUMAN | 0.58 | Heterogeneous nuclear ribonucleoproteins A2/B1 | 36 | 8.67 | 3.71 | 10.8 |
18 | ACTG_HUMAN | 0.66 | Actin, cytoplasmic 2 | 41.8 | 5.31 | 24 | 38.7 |
19 | EF1G_HUMAN | 0.46 | Elongation factor 1-gamma | 50.1 | 6.25 | 16.74 | 23.6 |
20 | EF2_HUMAN | 0.59 | Elongation factor 2 | 95.3 | 6.41 | 18.45 | 25.8 |
21 | FHL1_HUMAN | 0.64 | Four and a half LIM domain protein 1 | 36.3 | 9.25 | 15.7 | 23.5 |